Ciprofloxacin (Ciprofloxacin) is a broad-spectrum antibiotic belonging to the fluoroquinolone class, which has recently received approval from the FDA [
]. It is widely used in the treatment of bacterial infections, such as urinary tract infections, respiratory tract infections, and skin and soft tissue infections [
The drug is a common ingredient in all therapeutic drugs, but it is also widely used in clinical practice to prevent and treat infections in various areas, such as dermatology, surgery, and orthopedic procedures. In clinical practice, the drug is commonly prescribed to treat various infections, such as gram-negative and gram-positive bacteria. In this study, we examined the efficacy and safety of ciprofloxacin (Ciprofloxacin) for the treatment of bacterial infections in patients with urinary tract infections (UTIs).
This study was conducted to determine the efficacy and safety of ciprofloxacin (Ciprofloxacin) for the treatment of UTIs in patients with urinary tract infections (UTIs). The results of this study were reported in the Journal of Urology (Jurisciplinary Guideline), published in 2011 [
The ciprofloxacin was first approved by the FDA in 1987 [
In 1996, the FDA approved ciprofloxacin for the treatment of uncomplicated cystitis in patients with uncomplicated cystitis [
In 2000, the FDA approved ciprofloxacin in the treatment of pyelonephritis [
In 2009, the FDA approved the drug in the treatment of acute uncomplicated cystitis [
In 2008, the FDA approved ciprofloxacin in the treatment of urinary tract infections [
In 2013, the FDA approved the drug in the treatment of gonorrhea [
In 2013, the FDA approved ciprofloxacin for the treatment of urinary tract infections [
In 2015, the FDA approved the drug in the treatment of acute pyelonephritis [
In 2015, the FDA approved the drug in the treatment of acute uncomplicated pyelonephritis [
In 2019, the FDA approved the drug in the treatment of urinary tract infections [
In 2020, the FDA approved the drug in the treatment of acute pyelonephritis [
This study was carried out in accordance with the guidelines and recommendations of the Declaration of Helsinki and the International Conference on Harmonisation (ICH) [
The study protocol was approved by the local ethics committee of the Guangzhou Medical University. Written informed consent was obtained from patients or guardians of the patients.
The study was a single-center, retrospective observational study. The study was conducted in accordance with the principles of the Declaration of Helsinki, and the revised 2015 [
] and 2019 [
This study included patients who had UTIs in any of the follow-up time points of 12 weeks and 8 weeks. A detailed retrospective analysis was performed using the files of the patient’s medical record. The patients were excluded from the study if they were having UTIs in any of the follow-up time points.
Patients with a body mass index (BMI) ≥ 30 kg/m2 and a body mass index ≥ 28 kg/m2 had a body surface area (BSA) ≥ 20 m2. Patients with a body mass index ≥ 28 kg/m2 and a body surface area ≥ 10 m2 were excluded from the study. In addition, those with a body mass index ≥ 28 kg/m2 and a body surface area ≥ 20 m2 were excluded from the study.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use in Children 5 years and overAdults 18 years and over: use onlyConcomitant administration of cimetidine, with Inderal, Inderal X, Isordil, Orazol, Sildenafil, Viibol, Vioxx, Gemzar, Levodil, Oracea, Pimozide, Tizanac, or Celejanin.
Not to be used in place of the tablets:
Use as soon as possible after the dosing date as long as absolutely necessary. If it is almost time for the next dosing, skip the dosing and administer the following day as soon as possible: skip the dosing and then take the next dose at the usual time. Do not double the dose.
MedsGo Class not to be used in children 5 years and overMedsGo This medication is used to treat very high fever (38°C) caused byConcomitant administration of cimetidine, with Inderal, Inderal X, Isordil, Orazol, Sildenafil, Viibol, Vioxx, Gemzar, istalapace, Sildenafil Citrate, Ciprofloxacin Tablets, or Ciprofloxacin extended-release tablets (Ciprofloxacin Tablets XR); or with warfarin or other anti-platelet therapies. Not to be used if co-administered therapies are used: warfarin (e.g. rifampicin, rifabutin), or other anti-platelet therapies.
Ophthalmic ciprofloxacin comes as a solution (liquid) to apply to the eyes. Ciprofloxacin ophthalmic solution is usually used often, between once every 15 minutes to once every four hours while awake for seven to 14 days or longer. Ciprofloxacin ophthalmic ointment is usually applied three times a day for two days and then twice a day for five days. Use ciprofloxacin ophthalmic at around the same time every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Use ciprofloxacin ophthalmic exactly as directed. Do not use it more often than prescribed by your doctor.
You should expect your symptoms to improve during your treatment. Call your doctor if your symptoms do not go away or get worse, or if you develop other problems with your eyes during your treatment.
Use ophthalmic ciprofloxacin until you finish the prescription, even if you feel better. If you stop using ophthalmic ciprofloxacin too soon, your infection may not be completely cured and the bacteria may become resistant to antibiotics.
To instill the eye drops, follow these steps:
Wash your hands thoroughly with soap and water.
Check the dropper tip to make sure that it is not chipped or cracked.
Avoid touching the dropper tip against your eye or anything else; eyedrops and droppers must be kept clean.
While tilting your head back, pull down the lower lid of your eye with your index finger to form a pocket.
Hold the dropper (tip down) with the other hand, as close to the eye as possible without touching it.
Brace the remaining fingers of that hand against your face.
While looking up, gently squeeze the dropper soa single drop falls into the pocket made by the lower eyelid. Remove your index finger from the lower eyelid.
Close your eye for two to three minutes and tip your head down as though looking at the floor. Try not to blink or squeeze your eyelids.
Place a finger on the tear duct and apply gentle pressure.
Wipe any excess liquid from your face with a tissue.
If you are to use more than one drop in the same eye, wait at least five minutes before instilling the next drop.
Replace and tighten the cap on the dropper bottle. Do not wipe or rinse the dropper tip.
Wash your hands to remove any medication.
To apply the eye ointment, follow these instructions:
Avoid touching the tip of the tube against your eye or anything else; the tube tip must be kept clean.
Holding the tube between your thumb and forefinger, place it as near to your eyelid as possible without touching it.
Tilt your head backward slightly.
With your index finger, pull the lower eyelid down to form a pocket.
Squeeze a 1/2-inch (1.25cm) ribbon of ointment into the pocket made by the lower eyelid.
Blink your eye slowly; then gently close your eye for one to two minutes.
With a tissue, wipe any excess ointment from the eyelids and lashes. With another clean tissue, wipe the tip of the tube clean.
Replace and tighten the cap right away.
Continue to take ciprofloxacin even if you can not stop taking it, even if you start to feel better within a few days.
The brand name for the antibiotic Ciprofloxacin, ciprofloxacin, is ciprofloxacin. The drug belongs to the fluoroquinolone class of medications. It is used to treat a variety of bacterial infections, including urinary tract infections, pneumonia, gonorrhea, ear infections, and skin infections. It may also be used in the treatment of certain sexually transmitted diseases. Ciprofloxacin is commonly prescribed for the management of anthrax exposure. Ciprofloxacin works by inhibiting the synthesis of bacterial DNA, which is essential for the survival of bacteria. It is often used to treat anthrax infections. Ciprofloxacin is a quinolone that is used to treat anthrax and to prevent infection. Ciprofloxacin is used to treat certain infections, including aplastic anemia and sepsis. It is also used to treat anthrax after exposure to the anthrax bacteria. Ciprofloxacin works by killing the bacteria, which is essential for their survival. Ciprofloxacin is a broad spectrum antibiotic that is effective against a wide range of bacteria. It can be used to treat a variety of infections, including urinary tract infections, pneumonia, gonorrhea, and skin infections. Ciprofloxacin can be used to treat certain infections, such as aplastic anemia and sepsis. It can also be used to treat anthrax infections and to prevent infection.
Other uses of ciprofloxacin
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ciprofloxacin is not for use in pregnant or nursing women. However, ciprofloxacin is not intended to treat children under the age of 18. The use of ciprofloxacin for treating anthrax infections is not recommended.
Ciprofloxacin is not intended to treat urinary tract infections or other types of infections. However, ciprofloxacin can be used to treat anthrax infections.
Ciprofloxacin is a prescription-only antibiotic, and therefore, it is not appropriate for use by patients who are allergic to ciprofloxacin or other quinolone antibiotics. Ciprofloxacin should be used only after consulting a doctor.
Ciprofloxacin is a tetracycline antibiotic. It is used to treat infections caused by bacteria. Ciprofloxacin is used to treat certain types of infections caused by certain parasites. The use of ciprofloxacin for treating infections is not recommended.
Ciprofloxacin is also used to treat certain sexually transmitted diseases, including syphilis, chlamydia, gonorrhea, and genital warts.
Ciprofloxacin can be used to treat anthrax (bacterial infection) or to prevent infection (infection of the bladder, kidneys, or liver) in certain types of anthrax. Ciprofloxacin can also be used to treat infections caused by certain types of bacteria, such as gonorrhea. Ciprofloxacin is also used to treat certain types of infections, such as bacterial prostatitis (a painful or painful condition caused by the growth of prostatitis bacteria) and chlamydia (a sexually transmitted infection). Ciprofloxacin is also used to treat certain types of gonorrhea, including syphilis. Ciprofloxacin is also used to treat anthrax after exposure to the anthrax bacteria. Ciprofloxacin may be used for some other purposes.
Ciprofloxacin is not indicated for use in pregnant or nursing women. Ciprofloxacin is not intended to treat children under the age of 18.
Bakker, J. (1962). Pharmacokinetics of the fluoroquinolone (FQ) in normal and some patients with streptococcal pharyngitis: results of a double-blind, randomized trial.Am J Med13:527–534.
& Gullins, S. (1980). Fluoroquinolones. A review of their applications in infectious diseases.J Am Geriatr Med8:13–27.
Drug metabolism in streptococcal infections: a review of the literature.
Clinical signs of streptococcal pharyngitis: a review of the literature.
Gill, C. The incidence of infection in a single dose of the fluoroquinolones.
Lanning, T. & Baker, B. (1956). Clinical pharmacokinetics in children with streptococcal pharyngitis.Am J Clin Pharmacol4:3–9.
Kang, J. et al. Clinical and bacteriological evidence for the use of ciprofloxacin in the treatment of streptococcal pharyngitis.6:9–10.
Liu, H.7:10–12.
(1957).7:4–6.
Mannucci, J.8:5–6.
Rozano, F.8:6–9.
Salo, F.
Dalhoff, P.
Cipro, C.
Corta, L.
Klopfer, K.
Stade de France Pharmacy